Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9Q0P

Human anti-EBV gH/gL Fab (AMMO1) with G111T light chain mutation

Summary for 9Q0P
Entry DOI10.2210/pdb9q0p/pdb
DescriptorIgG heavy chain, IgG lambda light chain, GLYCEROL, ... (4 entities in total)
Functional Keywordsebv, antibody, fab, lambda, immune system
Biological sourceHomo sapiens (human)
More
Total number of polymer chains2
Total formula weight47347.65
Authors
Young, T. (deposition date: 2025-08-13, release date: 2025-12-03)
Primary citationJewel, Y.,Young, T.,Park, M.,Ly, K.,Gonzalez, A.,Mallett, T.C.,Williams, J.C.
Single-residue engineering of lambda ( lambda ) antibody light chains reduces conformational flexibility and enhances thermal stability.
Comput Struct Biotechnol J, 27:4730-4739, 2025
Cited by
PubMed Abstract: Monoclonal antibodies with lambda (λ) light chains are less commonly used in therapeutics due to their lower biophysical stability compared to kappa (κ) variants. Here, we identify a conserved glycine residue (Gly111) in the λ light chain hinge as a driver of large-scale Fab elbow-angle transitions. Using microsecond-scale molecular dynamics simulations of the EBV-neutralizing Fab AMMO1, we show that substituting Gly111 with threonine (G111T) increases the free energy barrier between conformational states, effectively arresting these transitions. Structural and biophysical analyses-including crystallography, differential scanning fluorimetry, and surface plasmon resonance-confirm that the mutation maintains Fab architecture and antigen binding while increasing thermal stability by up to 2.5 °C. The same mutation applied to a second λ-Fab yielded similar stabilization, and simulations of three clinical λ-Fabs revealed consistent reductions in elbow-angle flexibility. These results demonstrate a generalizable, single-residue engineering strategy to enhance the stability of λ-based Fabs without compromising function, with direct implications for therapeutic antibody development and manufacturability.
PubMed: 41245890
DOI: 10.1016/j.csbj.2025.10.045
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.08 Å)
Structure validation

250359

PDB entries from 2026-03-11

PDB statisticsPDBj update infoContact PDBjnumon